STOCK TITAN

[Form 4] Seacoast Banking Corp of Florida Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

On 31 Jul 2025, Alignment Healthcare (ALHC) Chief Legal & Administrative Officer Christopher J. Joyce filed a Form 4 disclosing the sale of 15,491 common shares at a weighted-average price of $16.0061 (range $16.00-$16.01). The trade was executed under a pre-arranged Rule 10b5-1 plan adopted 27 Nov 2024 and coded "S" (open-market sale).

Following the transaction, Joyce directly owns 374,531 shares. No derivative securities were bought or sold, and there were no other reportable transactions. The filing involves a single reporting person and indicates direct ownership only.

Il 31 luglio 2025, il Chief Legal & Administrative Officer di Alignment Healthcare (ALHC), Christopher J. Joyce, ha presentato un Modulo 4 che dichiara la vendita di 15.491 azioni ordinarie a un prezzo medio ponderato di 16,0061 $ (intervallo da 16,00 $ a 16,01 $). L'operazione è stata eseguita nell'ambito di un piano predefinito Rule 10b5-1 adottato il 27 novembre 2024 e contrassegnata con il codice "S" (vendita sul mercato aperto).

Dopo la transazione, Joyce possiede direttamente 374.531 azioni. Non sono stati acquistati o venduti strumenti derivati e non ci sono state altre transazioni da segnalare. La dichiarazione riguarda una sola persona e indica esclusivamente la proprietà diretta.

El 31 de julio de 2025, el Director Legal y Administrativo de Alignment Healthcare (ALHC), Christopher J. Joyce, presentó un Formulario 4 revelando la venta de 15.491 acciones ordinarias a un precio promedio ponderado de 16,0061 $ (rango de 16,00 $ a 16,01 $). La operación se realizó bajo un plan preestablecido Regla 10b5-1 adoptado el 27 de noviembre de 2024 y codificado como "S" (venta en mercado abierto).

Tras la transacción, Joyce posee directamente 374.531 acciones. No se compraron ni vendieron valores derivados, y no hubo otras transacciones reportables. La presentación involucra a una sola persona y solo indica propiedad directa.

2025년 7월 31일, Alignment Healthcare (ALHC)의 최고 법무 및 행정 책임자 Christopher J. Joyce가 Form 4를 제출하여 15,491 보통주를 가중평균 가격 $16.0061 (범위: $16.00-$16.01)에 매도했음을 공시했습니다. 이 거래는 2024년 11월 27일 채택된 Rule 10b5-1 계획에 따라 사전 조정된 방식으로 이루어졌으며, "S" 코드(시장 내 매도)로 표시되었습니다.

거래 이후 Joyce는 직접 374,531주를 보유하고 있습니다. 파생상품 매매는 없었으며, 다른 보고 대상 거래도 없습니다. 이 공시는 단일 보고자에 해당하며 직접 소유만을 나타냅니다.

Le 31 juillet 2025, le Chief Legal & Administrative Officer d'Alignment Healthcare (ALHC), Christopher J. Joyce, a déposé un formulaire 4 révélant la vente de 15 491 actions ordinaires à un prix moyen pondéré de 16,0061 $ (fourchette de 16,00 $ à 16,01 $). La transaction a été réalisée dans le cadre d'un plan préétabli Rule 10b5-1 adopté le 27 novembre 2024 et codée « S » (vente sur le marché ouvert).

Après la transaction, Joyce détient directement 374 531 actions. Aucun titre dérivé n'a été acheté ou vendu, et aucune autre transaction à déclarer n'a eu lieu. Le dépôt concerne une seule personne déclarante et indique uniquement une propriété directe.

Am 31. Juli 2025 reichte der Chief Legal & Administrative Officer von Alignment Healthcare (ALHC), Christopher J. Joyce, ein Formular 4 ein, in dem der Verkauf von 15.491 Stammaktien zu einem gewichteten Durchschnittspreis von 16,0061 $ (Spanne: 16,00 $–16,01 $) offengelegt wurde. Der Handel erfolgte im Rahmen eines vorab vereinbarten Rule 10b5-1 Plans, der am 27. November 2024 angenommen wurde, und wurde mit dem Code „S“ (Verkauf am offenen Markt) gekennzeichnet.

Nach der Transaktion besitzt Joyce direkt 374.531 Aktien. Es wurden keine Derivate gekauft oder verkauft, und es gab keine weiteren meldepflichtigen Transaktionen. Die Meldung betrifft eine einzelne Person und weist nur direkten Besitz aus.

Positive
  • Transparent execution under a disclosed Rule 10b5-1 plan, reducing concerns about opportunistic insider trading.
  • Officer retains 374,531 shares, maintaining significant equity alignment with shareholders.
Negative
  • Insider share sale of 15,491 shares may be interpreted as modest bearish sentiment despite being pre-planned.

Insights

TL;DR: Small 4% insider sale under 10b5-1 plan; neutral impact on ALHC valuation.

The 15,491-share sale represents roughly 4.1% of Joyce’s direct holdings. Execution via a pre-approved 10b5-1 plan signals planned diversification rather than an opportunistic move. Post-sale ownership of 374,531 shares keeps the officer materially aligned with shareholders. Size and context point to a neutral read-through for investors.

TL;DR: Transaction follows governance best practices; minimal governance risk.

Disclosure notes the 10b5-1 plan adoption date and provides weighted-average price details, enhancing transparency. No indications of derivative dealings or complex structures. Compliance with Section 16 reporting timelines appears intact. Overall, the filing reflects procedural discipline rather than a governance red flag.

Il 31 luglio 2025, il Chief Legal & Administrative Officer di Alignment Healthcare (ALHC), Christopher J. Joyce, ha presentato un Modulo 4 che dichiara la vendita di 15.491 azioni ordinarie a un prezzo medio ponderato di 16,0061 $ (intervallo da 16,00 $ a 16,01 $). L'operazione è stata eseguita nell'ambito di un piano predefinito Rule 10b5-1 adottato il 27 novembre 2024 e contrassegnata con il codice "S" (vendita sul mercato aperto).

Dopo la transazione, Joyce possiede direttamente 374.531 azioni. Non sono stati acquistati o venduti strumenti derivati e non ci sono state altre transazioni da segnalare. La dichiarazione riguarda una sola persona e indica esclusivamente la proprietà diretta.

El 31 de julio de 2025, el Director Legal y Administrativo de Alignment Healthcare (ALHC), Christopher J. Joyce, presentó un Formulario 4 revelando la venta de 15.491 acciones ordinarias a un precio promedio ponderado de 16,0061 $ (rango de 16,00 $ a 16,01 $). La operación se realizó bajo un plan preestablecido Regla 10b5-1 adoptado el 27 de noviembre de 2024 y codificado como "S" (venta en mercado abierto).

Tras la transacción, Joyce posee directamente 374.531 acciones. No se compraron ni vendieron valores derivados, y no hubo otras transacciones reportables. La presentación involucra a una sola persona y solo indica propiedad directa.

2025년 7월 31일, Alignment Healthcare (ALHC)의 최고 법무 및 행정 책임자 Christopher J. Joyce가 Form 4를 제출하여 15,491 보통주를 가중평균 가격 $16.0061 (범위: $16.00-$16.01)에 매도했음을 공시했습니다. 이 거래는 2024년 11월 27일 채택된 Rule 10b5-1 계획에 따라 사전 조정된 방식으로 이루어졌으며, "S" 코드(시장 내 매도)로 표시되었습니다.

거래 이후 Joyce는 직접 374,531주를 보유하고 있습니다. 파생상품 매매는 없었으며, 다른 보고 대상 거래도 없습니다. 이 공시는 단일 보고자에 해당하며 직접 소유만을 나타냅니다.

Le 31 juillet 2025, le Chief Legal & Administrative Officer d'Alignment Healthcare (ALHC), Christopher J. Joyce, a déposé un formulaire 4 révélant la vente de 15 491 actions ordinaires à un prix moyen pondéré de 16,0061 $ (fourchette de 16,00 $ à 16,01 $). La transaction a été réalisée dans le cadre d'un plan préétabli Rule 10b5-1 adopté le 27 novembre 2024 et codée « S » (vente sur le marché ouvert).

Après la transaction, Joyce détient directement 374 531 actions. Aucun titre dérivé n'a été acheté ou vendu, et aucune autre transaction à déclarer n'a eu lieu. Le dépôt concerne une seule personne déclarante et indique uniquement une propriété directe.

Am 31. Juli 2025 reichte der Chief Legal & Administrative Officer von Alignment Healthcare (ALHC), Christopher J. Joyce, ein Formular 4 ein, in dem der Verkauf von 15.491 Stammaktien zu einem gewichteten Durchschnittspreis von 16,0061 $ (Spanne: 16,00 $–16,01 $) offengelegt wurde. Der Handel erfolgte im Rahmen eines vorab vereinbarten Rule 10b5-1 Plans, der am 27. November 2024 angenommen wurde, und wurde mit dem Code „S“ (Verkauf am offenen Markt) gekennzeichnet.

Nach der Transaktion besitzt Joyce direkt 374.531 Aktien. Es wurden keine Derivate gekauft oder verkauft, und es gab keine weiteren meldepflichtigen Transaktionen. Die Meldung betrifft eine einzelne Person und weist nur direkten Besitz aus.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Arriola Eduardo J

(Last) (First) (Middle)
P.O. BOX 9012

(Street)
STUART FL 34995

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SEACOAST BANKING CORP OF FLORIDA [ SBCF ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/31/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/31/2025 A(1) 2,218 A $28.19 2,218 D(2)
Common Stock 28,404 D
Common Stock 558 D(3)
Common Stock 281 D(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Restricted stock issued from Seacoast's 2021 Incentive Plan for service as a Director in 2025, and deferred into director's account in Seacoast's Directors Deferred Compensation Plan
2. Held in Seacoast's Non-employee Directors Deferred Compensation Plan
3. Represents an unvested time-based restricted stock award granted on April 1, 2024, which shall vest over the three years in one-third increments, beginning on April 1, 2025, and on each anniversary thereafter, subject to continued employment
4. Held in IRA
Remarks:
/s/ Kathy L. Hsu as Power of Attorney for Eduardo J. Arriola 08/01/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many ALHC shares did Christopher J. Joyce sell?

He sold 15,491 common shares on 31 Jul 2025.

At what price were the ALHC shares sold?

The weighted-average sale price was $16.0061 per share, within a $16.00-$16.01 range.

Does Joyce still hold ALHC stock after the sale?

Yes. He directly owns 374,531 shares following the transaction.

Was the transaction part of a 10b5-1 trading plan?

Yes. The Form 4 states the sale was executed under a plan adopted on 27 Nov 2024.

Were any derivative securities involved in this filing?

No derivative securities were acquired or disposed of in the reported transaction.
Seacoast Bkg Corp Fla

NASDAQ:SBCF

SBCF Rankings

SBCF Latest News

SBCF Latest SEC Filings

SBCF Stock Data

2.43B
84.33M
1.4%
88.2%
3.39%
Banks - Regional
State Commercial Banks
Link
United States
STUART